Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,370,000 shares, an increase of 25.7% from the December 15th total of 2,680,000 shares. Based on an average daily volume of 286,800 shares, the days-to-cover ratio is presently 11.8 days. Currently, 7.4% of the company’s shares are sold short.

Astria Therapeutics Trading Down 3.2 %

Shares of ATXS traded down $0.25 during trading hours on Friday, reaching $7.50. 237,439 shares of the company traded hands, compared to its average volume of 279,490. The firm has a market cap of $423.23 million, a price-to-earnings ratio of -3.59 and a beta of 0.70. Astria Therapeutics has a 12-month low of $6.95 and a 12-month high of $16.90. The stock’s fifty day moving average price is $9.43 and its 200 day moving average price is $10.62.

Hedge Funds Weigh In On Astria Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its stake in Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after acquiring an additional 1,767,714 shares during the period. RA Capital Management L.P. raised its holdings in shares of Astria Therapeutics by 1.2% in the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after purchasing an additional 61,457 shares in the last quarter. Vestal Point Capital LP boosted its stake in shares of Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after purchasing an additional 750,000 shares in the last quarter. Millennium Management LLC increased its holdings in Astria Therapeutics by 13.5% during the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after buying an additional 218,518 shares during the period. Finally, Affinity Asset Advisors LLC raised its stake in Astria Therapeutics by 15.4% in the second quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock worth $8,878,000 after buying an additional 130,000 shares in the last quarter. 98.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Oppenheimer raised their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Monday, January 13th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Astria Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $25.60.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.